Amgen fails to block Novartis' Neupogen biosimilar

Novartis ($NVS) made history this month with the first FDA approval of a biosimilar, and now a judge's ruling has cleared the way for its launch. The drug, Zarxio, is a copy of Amgen's ($AMGN) blockbuster Neupogen, which is designed to boost white blood cell counts. Amgen sued in an effort to block Novartis from debuting its product in the U.S., but a federal judge denied its request for a temporary injunction, giving Novartis the green light to market its knockoff. More from FiercePharma

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.